COTA Healthcare focuses on improving cancer care through technology and data analytics. They analyze real-world data to provide insights that help healthcare providers, researchers, and pharmaceutical companies make informed decisions about cancer treatment. Their solutions aim to reduce variations in care quality and enhance patient outcomes. COTA's business model involves partnering with these clients, who pay for access to their data analytics tools. The goal of COTA Healthcare is to ensure that every cancer patient receives the most appropriate and effective care.

Med-Metrix

Horizon Healthcare Services

Varian Medical Systems

Celgene

Boston Millennia Partners

Foundation Medicine

Novartis

Hackensack Meridian Health

Memorial Sloan - Kettering Cancer Center

IQVIA

EW Healthcare Partners

Data & Analytics

Healthcare

COTA

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).

COTA and Guardant Health Partner to Advance Precision Oncology with AI and Real-World Data

What You Should Know:– COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers.– Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Enhancing Cancer Care with AI and Real-World DataElectronic health records contain a comprehensive account of a patient’s cancer care journey. However, their unstructured and incomplete format poses challenges for analysis. By infusing AI into data processing, COTA and Precision Health Informatics (PHI) aim to accelerate precision medicine at the point of care.Founded by oncologists, COTA focuses on precise, patient-first cancer care using real-world data. Their advanced analytics platform partners with life sciences companies, providers, and payers to improve cancer treatment. Learn more at cotahealthcare.com.Dr. C.K

Cota, Texas Oncology Partner To Advance Ai-Enabled Precision Medicine

What You Should Know:– A collaborative effort between COTA, PreciseDx, and Baptist Health South Florida seeks to revolutionize breast cancer recurrence risk assessment with the PreciseBreast™ (PDxBr) test. This AI-powered tool holds promise for faster, more accurate, and more affordable risk prediction compared to current methods.– By utilizing AI technology, PreciseBreast™ has the potential to offer patients a faster, more accurate, and more affordable way to assess their risk of recurrence and make informed treatment decisions in collaboration with their physicians.The Challenge of Breast Cancer RecurrenceOne in eight women in the US will face a breast cancer diagnosis in their lifetime. Understanding a patient’s specific risk of recurrence is crucial for informing treatment decisions. While existing gene-expression tests offer some insights, they have limitations:Limited Accuracy: Current testing methods may not capture the full picture of recurrence risk.Current testing methods may not capture the full picture of recurrence risk. High Cost: Gene-expression tests can be expensive, potentially limiting access for some patients.Gene-expression tests can be expensive, potentially limiting access for some patients. Delayed Results: Waiting two to four weeks for test results can delay critical treatment decisions.PreciseDx Aims to Transform Risk AssessmentPreciseDx’s PreciseBreast™ test utilizes artificial intelligence (AI) to analyze pathology slide images

New Ai Test Aims To Improve Breast Cancer Recurrence Prediction: Cota, Precisedx, And Baptist Health South Florida Collaborate

NEW YORK--(BUSINESS WIRE)--COTA, a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma. The partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer. COTA’s RWD offers critical insights into effective cancer treatment pathways and will provide valuable context on key patient populations. “Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame,” said Dr. C.K. Wang, an oncologist and COTA’s chief medical officer

Cota Announces Strategic Collaboration With Sanofi To Leverage Real-World Data And Ai To Accelerate Cancer Trials

What You Should Know:– COTA, a leading real-world data (RWD) and analytics company in oncology, has announced a new collaboration with Sanofi.– The strategic partnership aims to leverage RWD and artificial intelligence (AI) to accelerate clinical trials specifically focused on multiple myeloma, a cancer affecting white blood cells. The findings from this partnership have the potential to significantly impact future clinical trial designs for multiple myeloma.Unlocking Insights with Real-World DataCOTA’s expertise in RWD analysis will be instrumental in this initiative. Their comprehensive datasets offer valuable insights into real-world treatment pathways for cancer patients. This data will provide Sanofi with crucial context about key patient populations battling multiple myeloma.Focus on Multiple MyelomaThe initial project will center around multiple myeloma, a complex blood cancer. By analyzing RWD, the collaborators aim to:Unravel the Treatment Landscape: Gain a clearer understanding of the evolving treatment options for multiple myeloma.Gain a clearer understanding of the evolving treatment options for multiple myeloma. Inform Future Trials: The insights gleaned from RWD analysis will be used to design more efficient and targeted clinical studies in the future.The insights gleaned from RWD analysis will be used to design more efficient and targeted clinical studies in the future

Cota & Sanofi Partner To Leverage Real-World Data And Ai To Accelerate Cancer Trials

NEW YORK--(BUSINESS WIRE)--Today, COTA announced an extension of its research collaboration with ​​the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence. Under the collaboration, the two organizations will continue to jointly develop and implement research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. This collaboration serves as an extension of the agreement between COTA and the FDA established in 2018. To date, the partnership has yielded numerous oncology research studies that have been presented at the annual meetings of the American Society of Hematology (ASH) and the American Association of Cancer Research (AACR). The collaboration has been extended for an additional 5 years, focusing on leveraging real-world evidence to strengthen regulatory decision-making

Cota Announces Extended Collaboration With Fda To Advance The Use Of Real-World-Data In Cancer Research

What You Should Know:– COTA, a leader in real-world data and analytics solutions, today announced a five-year extension of its research collaboration with the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE).– The five-year extension builds upon a successful partnership established in 2018 and signifies a continued commitment to utilizing real-world data (RWD) to enhance cancer treatment and regulatory decisions.Building on a Successful FoundationThe initial collaboration, established in 2018, has yielded significant results. Joint research efforts have produced numerous oncology studies presented at prestigious conferences like the American Society of Hematology (ASH) and the American Association of Cancer Research (AACR).Leveraging RWD for Stronger Regulatory DecisionsThe extended collaboration focuses on harnessing the power of RWD to strengthen the FDA’s regulatory decision-making process. Key areas of focus include:RWD Study Design and Analysis: COTA and the FDA will collaborate on developing optimal RWD study designs and analytical methods for investigating clinically relevant questions.COTA and the FDA will collaborate on developing optimal RWD study designs and analytical methods for investigating clinically relevant questions. Priority Research Questions: Joint efforts will prioritize research questions that address critical aspects of cancer care, treatment, and patient outcomes.Joint efforts will prioritize research questions that address critical aspects of cancer care, treatment, and patient outcomes. New Data Sources: The collaboration will explore the utilization of new oncology data sources to support the OCE Scientific Collaborative’s mission.The collaboration will explore the utilization of new oncology data sources to support the OCE Scientific Collaborative’s mission

Cota And Fda Extend Collaboration To Advance Use Of Real-World Data In Cancer Research

Caris Life Sciences LogoWhat You Should Know:– Caris Life Sciences (Caris), a leader in AI-powered precision medicine, and COTA, Inc., a real-world data (RWD) and analytics expert, announced a strategic collaboration today.– The strategic partnership aims to revolutionize cancer treatment development and patient care by leveraging a powerful combination of data: Caris’ extensive molecular data and COTA’s real-world patient information.Real-World Data Fusion for Precision MedicineThis collaboration brings together unparalleled resources:Caris’ Molecular Expertise: Caris boasts a vast molecular database encompassing nearly 10 million tests, containing over 60 petabytes of data. This includes genomic, transcriptomic, proteomic, and imaging data, offering a comprehensive picture of each patient’s cancer.Caris boasts a vast molecular database encompassing nearly 10 million tests, containing over 60 petabytes of data. This includes genomic, transcriptomic, proteomic, and imaging data, offering a comprehensive picture of each patient’s cancer. COTA’s Real-World Insights: COTA contributes real-world data from over 2 million cancer patients treated across diverse healthcare settings. This data captures the actual treatment journeys and outcomes of patients, providing invaluable insights into real-world effectiveness.By combining these datasets, the collaboration aims to create a unique, large-scale, multi-modal data offering. This will empower researchers and pharmaceutical companies to:Develop More Effective Cancer Therapies: The comprehensive picture of patients’ molecular profiles and real-world treatment responses will guide the development of targeted and personalized cancer treatments.The comprehensive picture of patients’ molecular profiles and real-world treatment responses will guide the development of targeted and personalized cancer treatments

Caris And Cota Partner To Expand Cancer Care With Ai-Powered Rwd Platform

The combined power of Caris' DNA, RNA, and imaging data with COTA's curated clinical data strengthens the offering to drive next-gen therapeutic development and advance patient careIRVING, Texas and NEW YORK, April 30, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics company used by the world's leading pharmaceutical companies, today announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care.The combination of the breadth and depth of Caris' genomic, transcriptomic, proteomic and imaging data and COTA's high-quality curated clinical data that captures the treatment journeys and outcomes of cancer patients will result in a broad real-world, multi-modal data offering, at scale, to power the next wave of cancer therapeutics.Caris' partnership with COTA enables biopharma to leverage a more complete dataset to power research and AI approaches Post this"Caris' partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development. This breadth of data allows the flexibility to build specific cohorts for understanding mechanisms of resistance, determinants of response and relevant biomarkers to improve success of their clinical trials," said Brian Lamon, PhD, Chief Business Officer at Caris.As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, multi-modal database generated from nearly 10 million tests that contains more than 60 petabytes of oncology-specific genomic, transcriptomic, proteomic and imaging data. Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage for every viable sample."By combining COTA's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life," said C.K. Wang, MD, Chief Medical Officer at COTA.COTA's data includes more than two million cancer patients who have received treatment across 200 sites of care in both academic medical centers and community practices in rural and urban settings, providing a powerful representative picture of cancer care across the U.S. COTA synthesizes those records into data that life sciences companies use to develop better, more personalized cancer treatments.About Caris Life SciencesCaris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI

Caris Life Sciences And Cota, Inc. Announce Collaboration To Expand Collective Multi-Modal Data Offering

COTA launches new real-world data platform to accelerate cancer research and advance generative AI models in oncology.

COTA launches new real-world data platform to accelerate cancer research and advance generative AI models in oncology

Data analytics for cancer care improvement

COTA

Data analytics for cancer care improvement

COTA

Data analytics for cancer care improvement

About

Simplify's Take

What believers are saying

What critics are saying

What makes COTA unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

There are no jobs for COTA right now.